HOME >> MEDICINE >> NEWS
ENDEAVOR III Trial reports key findings on new-generation stent

(May 10, 2007ORLANDO, FL) -- New data reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 912, 2007, in Orlando, FL, will offer clues to the fate of a new-generation drug-eluting stent that is vying for a place in the treatment of coronary artery disease.

The Endeavor III trial randomly assigned 436 patients treated at 30 medical centers in the United States to treatment with the investigational Endeavor stent (Medtronic, Minneapolis) or the Cypher stent (Cordis Johnson & Johnson, Miami Lakes, FL). The Endeavor stent is coated with zotarolimus, a medication that, like the Cyphers sirolimus coating, reduces renarrowing of the artery by preventing the growth of scar tissue inside the stent.

Initial data showed that procedural success was higher with the new Endeavor stent, which is more flexible and is considered easier to implant than the Cypher stent. However, at 8 months, the Endeavor stent fell short in angiographic studies, showing significantly greater scar tissue growth, or late loss, in the inner diameter of the artery as compared to the Cypher stent. At 12 months, clinical outcomes were equivalent with the two stents: The combined rates of death, heart attack, and repeat procedures were 8.2 percent in both groups of patients.

At the Orlando SCAI meeting, Martin Leon, M.D., FSCAI, a professor of medicine and associate director of the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York City, will report 2-year clinical outcomes from the Endeavor III trial.

"Long-term follow-up will further clarify not only safety with the zotarolimus-eluting stent but also whether early angiographic disparities translate into differences in late clinical restenosis," he said.

The Endeavor III trial is 1 of 5 studies gathering the data necessary for market approval of the new stent by the Food and Drug Administra
'"/>

Contact: Kathy Boyd David
kbdavid@scai.org
717-422-1181
Society for Cardiovascular Angiography and Interventions
10-May-2007


Page: 1 2

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. NIH names Clinical Trial Units for the Microbicide Trials Network
5. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
6. The Public Library of Science launches the new open access journal PLoS Clinical Trials
7. Trial shows vaccine against cervical cancer provides long-term protection
8. Trial shows malaria vaccine could protect young children from disease for 18 months
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ENDEAVOR III Trial reports key findings new generation stent

(Date:5/18/2013)... KY (PRWEB) May 18, 2013 During ... hearing loss should consider the legal protections they have, ... when problems arise with their child’s treatment or hearing ... , Since 1927, the American Speech-Language-Hearing Association has used ... disorders and to promote treatment, such as cochlear implants, ...
(Date:5/18/2013)... Rosa, CA (PRWEB) May 18, 2013 ... . The simple to read reviews and comprehensive comparisons ... and impartial home security reviews. 6Webs.com just recently finished ... alarm system providers. , Tim Smythe from 6Webs.com reports, ... security systems due to their ease of use, expandability ...
(Date:5/18/2013)... The California College of Ayurveda Spa is ... Ayurvedic Spa , the client receives stress relief therapies ... lifestyle recommendations and stress management techniques by a Clinical ... traditional healthcare system of India. It is based on ... basis for all optimum health. Ayurveda believes that where ...
(Date:5/18/2013)... Dr. Robert Tracey, an area leader in ... his knowledge of the root causes of sleep apnea to ... being Better Sleep Month, Dr. Tracey points out estimates revealing ... disorder, and sleep apnea is one of the most common ... essentially stop breathing at different times while sleeping. When this ...
(Date:5/18/2013)... 2013 John Ravera, D.D.S., a Newport ... a new member to his dental team, Courtney Marino. , ... field for over 10 years. She received her degree from ... elected a member of Sigma Pi Alpha, a national honor ... working with patients of all ages, helping them understand the ...
Breaking Medicine News(10 mins):Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Best Wireless Home Security System Companies Released by 6Webs.com 2Health News:Ayurveda Spa Treatments Now Offered at the California College of Ayurveda Panchakarma Center 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 3Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2
(Date:5/16/2013)... YORK , May 16, 2013 Developers of ... sends patient reminders have emerged as grand prize winners in ... innovation challenge funded by Boehringer Ingelheim and organized by ... Stein , John Langhauser and ... from the United States will ...
(Date:5/16/2013)... 16, 2013  Actinium Pharmaceuticals, Inc. (OTCBB: ... targeted payload immunotherapeutics for treatment of advanced ... TAT: Target Alpha Therapy (TAT) international symposium ... Pharmaceuticals, clinical programs.  The abstract entitled "Alpha-Particle ... and Actinium-225" has been accepted for oral ...
(Date:5/16/2013)... 16, 2013  Lakewood-Amedex Inc., a leading developer ... recent series of in vitro studies ... of antimicrobials, named bisphosphocins, function through a completely ... resulting in rapid direct bacterial killing.  These studies ... be superior to ciprofloxacin.  The studies revealed the ...
Breaking Medicine Technology:Wireless Pill Bottle Wins Healthcare Innovation World Cup 2Wireless Pill Bottle Wins Healthcare Innovation World Cup 3Wireless Pill Bottle Wins Healthcare Innovation World Cup 4Wireless Pill Bottle Wins Healthcare Innovation World Cup 5Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference 2Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference 3Lakewood-Amedex Announces Results Demonstrating The More Rapid Direct Bactericidal Activity Of Novel Bisphosphocin Class Of Antimicrobials 2Lakewood-Amedex Announces Results Demonstrating The More Rapid Direct Bactericidal Activity Of Novel Bisphosphocin Class Of Antimicrobials 3Lakewood-Amedex Announces Results Demonstrating The More Rapid Direct Bactericidal Activity Of Novel Bisphosphocin Class Of Antimicrobials 4
Cached News: